Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | ACACB | O00763 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26238861 | 1.00 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL25201048 | 1.00 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL25215944 | 0.91 | TAAR1 (0.62) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL25215945 | 0.91 | TAAR1 (0.62) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL25391470 | 0.89 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL26983120 | 0.89 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL25391472 | 0.89 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL10842792 | 0.87 | TAAR1 (0.65) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL25132152 | 0.86 | TAAR1 (0.63) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL25858222 | 0.86 | TAAR1 (0.63) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208920-A1 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EMPATHBIO, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-4065473-A | Intermediates in the preparation of 2,3,4,5-tetrahydro-1H-3-benzazepines | HOFFMANN-LA ROCHE INC. (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208920-A1 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | COMT, PNMT, DDT | TAAR1 149/4885SLC6A2 150/4885SLC6A4 109/4885 |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | SLC6A3, DBH, PNMT | TAAR1 103/4885SLC6A2 10/4885SLC6A4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.